Program
cromolyn
Also written as “Cromoglicate”, “Cromolyn Sodium (34.2 mg BID)” and “Cromolyn Sodium (17.1 mg BID)”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Alzheimer Disease · Adenocarcinoma of Lung · Psoriasis · Mastocytosis, led by 4 companies.
Drug pageCromolyn: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AZTherapies | 40 open or running | phase 3since Sep 10, 2015 | Sep 10, 2015 | none ahead |
| LEO Pharmaits history only | 20 open or running | phase 2since Jul 11, 2012 | Jul 11, 2012 | none ahead |
| Carcinexits history only | 11 open or running | phase 1since Jun 16, 2026 | Jun 16, 2026 | Jun 2027phase 1 · NCT07675876 |
| PhenoNetits history only | 11 open or running | phase 2since Aug 19, 2025 | Aug 19, 2025 | Mar 2027phase 2 · NCT07142291 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AZTherapies only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 10, 2015First study: phase 3 study in Alzheimer DiseaseFirst studyNCT02547818 · 620 enrolled · United States, Australia, Bulgaria and more
- Jun 26, 2017Phase 2 study in Ischemic StrokeNCT03202147
- Jun 3, 2020Phase 2 study in Amyotrophic Lateral SclerosisNCT04428775 · 12 enrolled · United States
- Sep 17, 2020Phase 1 study in Alzheimer DiseaseNCT04570644 · 56 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 AZTherapies leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04570644Alzheimer Disease · United States | 1 | Completed | Jan 18, 2021 | 56 |
| NCT04428775Amyotrophic Lateral Sclerosis · United States | 2 | Terminated | Oct 1, 2021 | 12 |
| NCT03202147Ischemic Stroke | 2 | Withdrawn | Dec 2024 | 0 |
| NCT02547818Alzheimer Disease · United States, Australia, Bulgaria and more | 3 | Completed | Nov 13, 2020 | 620 |
How it is read
Names in the registry
- “Cromoglicate”, 2 entries
- “Cromolyn Sodium (34.2 mg BID)”, 1 entry
- “Cromolyn Sodium (17.1 mg BID)”, 1 entry
- “Cromolyn Sodium”, 1 entry
- “ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)”, 1 entry
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 2 studies
- Alzheimer Disease, 2 studies
- Adenocarcinoma of Lung, 1 study
- Psoriasis, 1 study
- Mastocytosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.